Letrozin

Letrozole, the active ingredient in Letrozin, is a aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of estrogen‑receptor positive breast cancer in postmenopausal women, including adjuvant and metastatic settings.

GNH USA supplies Letrozin as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozin, an aromatase inhibitor, is indicated for conditions driven by estrogen signaling in breast cancer. - Estrogen receptor‑positive breast cancer in postmenopausal women: lowers estrogen production to inhibit tumor growth. - Adjuvant treatment of early breast cancer: reduces risk of disease recurrence after surgery. - Metastatic breast cancer: helps control disease progression in advanced cases.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth. - Joint pain: aching or stiffness in joints. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: tension or throbbing pain. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe liver injury: elevated enzymes or jaundice. - Pulmonary embolism: sudden shortness of breath. - Deep vein thrombosis: leg swelling and pain. - Bone fracture: increased risk due to reduced estrogen. - Allergic reaction: rash, swelling, or anaphylaxis. - Elevated cholesterol: changes in lipid profile.

Patients should be monitored for specific safety considerations before and during therapy. - Bone health: assess bone mineral density regularly. - Liver function: perform baseline and periodic liver enzyme tests. - Cardiovascular risk: evaluate history of thrombosis or clotting disorders. - Hot flashes: counsel on lifestyle measures to mitigate. - Premenopausal status: avoid use in women who are not postmenopausal. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Tamoxifen: antagonistic effect on estrogen blockade. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower letrozole levels. - Estrogen‑containing hormone therapy: counteracts intended estrogen suppression. - Certain anticonvulsants (e.g., phenytoin): reduce drug exposure. - Antifungal agents that inhibit CYP3A4 (e.g., ketoconazole): may increase exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect. - SSRIs (e.g., fluoxetine): may affect metabolism. - NSAIDs: increased risk of gastrointestinal irritation. - Cholesterol‑lowering statins: monitor lipid changes. - Thyroid hormone replacement: assess thyroid function periodically.